Hansoh's HS-20093 receives breakthrough therapy designation in China

Hansoh Pharmaceutical Group Company Limited (HKEX: 3692) announced that its self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has been granted Breakthrough-Therapy-Designated Drug status by the National Medical Products Administration (“NMPA”) of China. This designation applies to locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations that has progressed or recurred following platinum-based chemotherapy. HS-20093, an investigational ADC, is composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor. It is under development for multiple cancers. Previously, HS-20093 received Breakthrough Therapy Designation for extensive-stage small-cell lung cancer (ES-SCLC) in November 2024 and for osteosarcoma in February 2025.